Edition:
India

Voyager Therapeutics Announces Restructured Gene Therapy Relationship With Sanofi Genzyme


Monday, 17 Jun 2019 

June 17 (Reuters) - Voyager Therapeutics Inc ::VOYAGER THERAPEUTICS ANNOUNCES RESTRUCTURED GENE THERAPY RELATIONSHIP WITH SANOFI GENZYME AND PORTFOLIO UPDATE.VOYAGER THERAPEUTICS INC - GAINS WORLDWIDE RIGHTS TO VY-HTT01 FOR HUNTINGTON'S DISEASE.VOYAGER THERAPEUTICS INC - GAINS WORLDWIDE RIGHTS TO VY-HTT01 FOR HUNTINGTON'S DISEASE.VOYAGER THERAPEUTICS INC - RESOURCES TO BE REALLOCATED TO VY-HTT01 AND OTHER PROGRAMS; INTENDS TO SEEK A PARTNER FOR SOD1 ALS PROGRAM.VOYAGER THERAPEUTICS INC - RESOURCES TO BE REALLOCATED TO VY-HTT01 AND OTHER PROGRAMS; INTENDS TO SEEK A PARTNER FOR SOD1 ALS PROGRAM.VOYAGER THERAPEUTICS INC - NO LONGER EXPECTS TO FILE AN IND APPLICATION FOR VY-SOD102 IN 2019.VOYAGER THERAPEUTICS INC - IN CONSIDERATION OF RIGHTS RETURNED, VOYAGER HAS AGREED TO MAKE A $10 MILLION UPFRONT PAYMENT TO SANOFI GENZYME.VOYAGER THERAPEUTICS INC - SANOFI GENZYME OBTAINS EXCLUSIVE OPTION RIGHTS TO SELECT NOVEL AAV CAPSIDS OWNED OR CONTROLLED BY VOYAGER FOR EXCLUSIVE USE.VOYAGER THERAPEUTICS INC - AN ADDITIONAL $10 MILLION MILESTONE PAYMENT IS DUE TO SANOFI GENZYME.VOYAGER THERAPEUTICS INC - PRECLINICAL STUDIES ARE UNDERWAY WITH VY-HTT01.VOYAGER - SANOFI GENZYME'S OPTION TO ACQUIRE DEVELOPMENT AND COMMERCIALIZATION RIGHTS TO A FUTURE VOYAGER CNS ORPHAN PROGRAM IS TERMINATED.VOYAGER THERAPEUTICS INC - VOYAGER INTENDS TO SEEK A PARTNER TO ADVANCE ITS PRECLINICAL PROGRAM FOR SOD1 ALS.VOYAGER THERAPEUTICS INC - VOYAGER NO LONGER EXPECTS TO FILE AN IND APPLICATION FOR VY-SOD102 IN 2019.